Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus.

@article{Nicolai1997DurationOA,
  title={Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus.},
  author={H von Nicolai and R Brickl and H Eschey and Andreas Greischel and Gerhard Heinzel and Evelyn K{\"o}nig and J{\"o}rg Limmer and Edgar Rupprecht},
  journal={Arzneimittel-Forschung},
  year={1997},
  volume={47 3},
  pages={247-52}
}
The duration of action and the pharmacokinetics of gliquidone (1-cyclohexyl-3-[[4-[2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1, 3-dioxo-2(1H)-isochinolyl)ethyl]phenyl]-sulfonyl]-urea, AR-DF 26 SE, CAS 33342-05-1, Glurenorm, Beglynor) were investigated in 32 patients with non-insulin-dependent (type 2) diabetes mellitus over 16 h. In a single-blinded cross-over design vs. placebo, one 30 mg tablet gliquidone was administered 15 min before breakfast. Concomitant to the measurement of glucose and… CONTINUE READING